论文部分内容阅读
目的:探究溃疡性结肠炎患者用药美沙拉嗪、双歧杆菌后,其细胞因子、免疫细胞水平变化情况。方法:选取2014年3月~2015年9月期间我院门诊部门收治的溃疡性结肠炎患者86例,本次临床分组采用双盲法将患者分为两组单一组43例、治疗组43例。单一组使用双歧杆菌治疗,治疗组在此基础上加用美沙拉嗪,检测治疗前后血清中IL-6、IL-17水平以及CD3、CD4含量变化。结果:入院时两组IL-8、IL-6水平比较差别无意义,P>0.05,服药后治疗组较单一组IL-8、IL-6水平改善效果好,P<0.05;治疗前两组CD3、CD4含量比较差别无意义,P>0.05,治疗后治疗组较单一组CD3、CD4含量增加情况好,P<0.05。结论:临床对溃疡性结肠炎患者进行治疗时,使用美沙拉嗪、双歧杆菌药物联合治疗,患者恢复效果好,细胞因子、免疫因子改善好。
Objective: To investigate the changes of cytokines and immune cells in patients with ulcerative colitis treated with mesaprazine and Bifidobacterium. Methods: Totally 86 patients with ulcerative colitis treated in our outpatient department from March 2014 to September 2015 were enrolled in this study. The patients were divided into two groups according to a double-blind method: 43 cases in the single group, 43 cases in the treatment group . Bifidobacterium alone was used in the treatment group. Mesalazine was added to the treatment group, and the levels of IL-6, IL-17 and the contents of CD3 and CD4 in the serum before and after treatment were detected. Results: There was no significant difference in the levels of IL-8 and IL-6 between the two groups on admission (P> 0.05). After treatment, the improvement effect of IL-8 and IL-6 in the treatment group was better than that in the single group CD3, CD4 content of the difference was meaningless, P> 0.05, the treatment group than the single group CD3, CD4 levels increased, P <0.05. Conclusion: The clinical treatment of patients with ulcerative colitis, the use of Mesalazine, Bifidobacterium drug combination therapy, patients with good recovery, cytokines, immune factors improved well.